DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The Nerve Repair and Regeneration market worldwide is projected to grow by US$7.1 Billion, driven by a compounded growth of 12.1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the region's size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/dhc95v

Read the original:

Global Nerve Repair and Regeneration Market (2019 to 2025) - Analysis, Trends, and Forecasts - ResearchAndMarkets.com - Business Wire

Adipose Derived Stem Cell Therapy Market Research Report 2020, is mostly driven by the improved taking on of Adipose Derived Stem Cell Therapy across small and medium-sized enterprises. Worldwide Adipose Derived Stem Cell Therapy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Adipose Derived Stem Cell Therapy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2357

About Adipose Derived Stem Cell Therapy Market Report

This research report categorizes the global Adipose Derived Stem Cell Therapy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

Adipose Derived Stem Cell Therapy Market Dynamics in the world mainly, the worldwide 2020-2026 Adipose Derived Stem Cell Therapy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Adipose Derived Stem Cell Therapy Market Report:

Adipose Derived Stem Cell Therapy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Adipose Derived Stem Cell Therapy, Market Driving Factor Analysis of Adipose Derived Stem Cell Therapy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Adipose Derived Stem Cell Therapy, and Cost and Gross Margin Analysis of Adipose Derived Stem Cell Therapy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Adipose Derived Stem Cell Therapy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Adipose Derived Stem Cell Therapy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Adipose Derived Stem Cell Therapy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2357

Further in the report, the Adipose Derived Stem Cell Therapy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Adipose Derived Stem Cell Therapy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Adipose Derived Stem Cell Therapy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Originally posted here:

Adipose Derived Stem Cell Therapy Market Increasing the Growth Worldwide: Industry Analysis, Growth, Drivers, Limitations, Regions, Forecast 2026 ...

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the Harvard University team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospital's Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely.

For the new study, Harvard researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper.

These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita. These compounds boosted TERC levels in those stem cells and restored telomeres to their normal length. However, rather than a scattergun approach, the team really wanted to test for safety and see if the treatment could precisely target stem cells carrying the right ingredients for telomerase formation.

More specifically, the team wanted to see if this could be achieved by having the PAPD5-inhibiting drugs recognize and respond to another important component of telomerase, a molecule called TERT. To do so, in the next round of experiments the team used human blood stem cells and triggered mutations in the PARN gene that give rise to dyskeratosis congenita. These were then implanted into mice that were treated with the compounds, with the team finding the treatment boosted TERC, restored telomere length in the stem cells and had no ill effects on the rodents.

This provided the hope that this could become a clinical treatment, says Nagpal.

The team will now continue its work in an effort to prove these small molecules are a safe and effective way to apply the brakes to dyskeratosis congenita, other diseases, and possibly aging more broadly.

We envision these to be a new class of oral medicines that target stem cells throughout the body, Agarwal says. We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.

The research was published in the journal Cell Stem Cell.

Source: Boston Childrens Hospital via Harvard University

See the original post here:

Molecules identified that reverse cellular aging process - New Atlas

The presented market report on the global Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is a comprehensive analysis of the leading parameters that are likely to determine the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the forthcoming decade. Further, the study dives in deep to investigate the micro and macro-economic factors that are projected to influence the global scenario of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period (2019-2029).

The market study reveals that the Rheumatoid Arthritis Stem Cell Therapy market is expected to grow at a CAGR of ~XX% and reach a value of ~USXX by the end of 2029. The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynamics of the Rheumatoid Arthritis Stem Cell Therapy market in the assessment period. The market study predicts the course of the global Rheumatoid Arthritis Stem Cell Therapy market post the COVID-19 pandemic and offers resourceful insights to market players pertaining to their business continuity strategies and more.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segmentation

The report bifurcates the Rheumatoid Arthritis Stem Cell Therapy market into multiple segments to provide a clear picture of the Rheumatoid Arthritis Stem Cell Therapy market at a granular level. The key segments covered in the report include region, product type, application, and more.

Competitive landscape

The growth projection of each of these segments and sub-segments is accurately tracked in the report along with east-to-understand graphs and tables. Further, the market share, size, value, and Y-o-Y growth of the Rheumatoid Arthritis Stem Cell Therapy market segments are included in the report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Essential Takeaways from the Rheumatoid Arthritis Stem Cell Therapy Market Report

Important queries related to the Rheumatoid Arthritis Stem Cell Therapy market addressed in the report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Why Choose Fact.MR

Excerpt from:

Potential Impact of COVID-19 on Rheumatoid Arthritis Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2034 2018 to 2028 -...

Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19).

Additionally, Mount Sinai indicated that they will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19.

Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.

Mount Sinai began administering remestemcel-L to patients in late March under the FDAs compassionate use program. The therapy was given to 10 patients with moderate to severe cases of COVID-19-related acute respiratory distress syndrome (ARDS), most of whom were on ventilators, and the doctors saw encouraging results.

We are encouraged by what we have seen so far and look forward to participating in the randomized controlled trial starting soon that would better indicate whether this is an effective therapy for patients in severe respiratory distress from COVID-19, Keren Osman, MD, medical director of the Cellular Therapy Service in the Bone Marrow and Stem Cell Transplantation Program at The Tisch Cancer Institute at Mount Sinai and associate professor of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, said in a press release.

The randomized clinical trial evaluating the therapeutic benefit and safety of remestemcel-L will be conducted at Mount Sinai, which will serve as the clinical and data coordinating center. The stem cell therapy will be evaluated in 240 patients with COVID-19-related ARDS in the US and Canada. Moreover, the trial will be conducted as a public-private partnership between the Cardiothoracic Surgical Trials Network.

The coronavirus pandemic has caused exponential increases of people suffering with acute respiratory distress syndrome, requiring intubation and mechanical ventilation with many dying, Annetine Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy at the Icahn School of Medicine at Mount Sinai, said in a press release. We have designed a clinical trial that will expeditiously determine whether the stem cell therapy will offer a life-saving therapy for a group of patients with a dismal prognosis.

Remestemcel-L consists of mesenchymal stem cells. The therapy was previously assessed in a phase III trial in children who had graft-versus-host disease (GVHD), which can occur after bone marrow transplants. Further, the inflammation that occurs in GVHD is the result of a cytokine storm. A similar cytokine storm has been found to take place in patients with COVID-19 who develop acute respiratory distress syndrome.

These stem cells have shown excellent response rates in severe graft-versus-host disease in children, John Levine, MD, professor of Hematology, Medical Oncology, and Pediatrics at the Icahn School of Medicine at Mount Sinai, who is also the co-director of the Mount Sinai Acute GVHD International Consortium (MAGIC), said in a press release. Mesenchymal stem cells have a natural property that dampens excessive immune responses.

Some institutions have also begun testing anti-IL-6 agents, such as tocilizumab (Actemra), for the treatment of cytokine release syndrome in patients with COVID-19 who develop acute respiratory distress syndrome.

Reference:

Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients [news release]. New York, NY. Published April 9, 2020. newswise.com/coronavirus/mount-sinai-leading-the-way-in-innovative-stem-cell-therapy-for-covid-19-patients/?article_id=729684&sc=dwhr&xy=10019792. Accessed April 15, 2020.

Read the original post:

Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 - Cancer Network

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs. CAR-T cell therapies also hold promise for patients with hematologic malignant neoplasms that are unresponsive or resistant to standard treatments, researchers said.

The treatment involves harvesting and reengineering an individuals own cells to attack specific malignant cells. CAR-T cells were initially developed using knowledge gleaned from allogeneic stem cell transplantsthat donor mature immune cells can attack healthy cells in the recipient patient.

In an economic evaluation, researchers used a decision-tree model to document patient clinical outcomes and costs, using only hypothetical patients and facilities. Excluding the CAR T-cell acquisition cost, researchers found hospitalization and office visits comprised 65.3% of the costs in inpatient settings and 48.4% of the costs in outpatient settings. Specifically, outpatient administration of CAR T-cell therapy in nonacademic specialty oncology networks was associated with a $32,987 (40.4%) reduction in total costs. Sensitivity analyses were carried out to address assumptions made to build the model.

Before the approval of CAR T-cell therapy, the available treatments for patients with relapsed or refractory LBCL included high-dose chemotherapy, salvage chemotherapy, and autologous hematopoietic stem cell transplantation (auto-HSCT); however, the prognosis after these treatments is often poor, authors said.

Researchers analyzed a predefined period from lymphodepletion to 30 days after the receipt of CAR T-cell infusion, in order to account for potential incidences of adverse events. Data were collected from several sources including theHealthcare Cost and Utilization Project National Inpatient Sample and the Medicare Hospital Outpatient Prospective Payment System. Investigators used secondary literature to inform model inputs.

Total cost of therapy included any costs associated with lymphodepletion, acquisition and infusion of CAR T-cells and management of acute adverse events.

The model also showed:

In this scenario, the model found patients who received CAR T-cell therapy in a nonacademic specialty oncology network setting would save $27,294 compared with the inpatient setting. In addition, in the scenario analysis the decrease in incremental cost reductions was associated with a lower overall incidence of AEs, which reduced the consequences of associated AE management costs, while the monitoring required at baseline was held constant.

The results indicate CAR T-cell therapy with a better safety profile may be more economical and could further leverage the outpatient site of care, researchers said. They concluded, The potential availability of CAR T-cell therapies with lower AE rates that are suitable for outpatient administration may reduce the total costs of care.

One limit to the study highlighted by the authors is the fact that outpatient administration may not be an option for all patients with LBCL.Eligibility can be contingent on the patients health status, support system, or the availability of housing near hospitals.

However, some specialists predict a gradual shift of all CAR T-cell therapies to the outpatient setting. Part of the reason for that [shift] is the way that it's reimbursed as an outpatient therapy is slightly more favorableso, financially it is better to do that, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSWs Harold C. Simmons Comprehensive Cancer Center.

He continued, The problem is that these are very toxic treatments, and that many of the patients are not going to be manageable in the outpatient setting; but I do see that as one of the factors which is influencing a slow transition to outpatient CAR-Ts.

Expanded access to novel therapies in immune-oncology (IO) like CAR T-cell therapy also remains a priority among community level oncologists. Reimbursement, operational, and medical challenges associated with cellular therapy inhibit widespread uptake of the therapy, explained Lee Schwartzberg, MD, FACP, chief medical officer and board member at OneOncology. Only a small number of patients, frankly, have been treated with the first-generation CAR-T cells. So we need to develop new technologies and new operational models to do this, he said in an interview with The American Journal of Managed Care.

Reference

Lyman GH, Nguyen A, Snyder S, et al. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma [published online April 6, 2020]. JAMA Netw Open. doi: 10.1001/jamanetworkopen.2020.2072.

Read more:

What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network

The Animal Stem Cell Therapy report provides independent information about the Animal Stem Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Animal Stem Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Animal Stem Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Animal Stem Cell Therapy Market: Products in the Animal Stem Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Animal Stem Cell Therapy Market Report Covers the Following Segments:

Segment1: By Type, Dogs, Horses, Others, By Application, Veterinary Hospitals, Research Organizations

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Animal Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Animal Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Animal Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Animal Stem Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Animal Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Animal Stem Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Animal Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/ipaas-integration-platform-as-a-service-market-size-share-application-analysis-regional-outlook-growth-trends-top-key-players-and-competitive-strategiesforecast-to-2025-2020-04-24?tesla=y

https://www.marketwatch.com/press-release/microwave-transmission-equipment-market-2020-share-trends-segmentation-and-forecast-by-2025-cagr-of-314-2020-04-24-61763810?tesla=y

http://marketwatch.com/press-release/military-drone-market-share-size-future-demand-global-research-top-leading-player-emerging-trends-region-by-forecast-to-2025-2020-04-24?tesla=y

Read more here:

Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty

Sangamo Therapeutics has struck a deal with Mogrify to gain access to a source of cells for use in its allogeneic CAR-Treg therapies. The agreement sees Sangamo pay an upfront fee to get Mogrify to apply its direct cell conversion technology to the generation of regulatory T cells.

Ready access to sources of cells has emerged as a key area of focus for developers of off-the-shelf cell therapies, leading to deals such as Allogenes alliance with Notch Therapeutics. That deal, like other moves by allogeneic cell therapy players, reflected a desire to replace the finite donated T cells used in early off-the-shelf prospects with renewable, more scalable sources of starting materials.

Sangamo has identified Mogrify as a provider of such materials. Mogrify put itself on the map early last year when Darrin Disley, the former leader of Horizon Discovery, joined the startup as CEO and invested in its seed round. Months later, Mogrify raised a $16 million series A round.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Mogrify attracted the interest of Disley, Sangamo and an investor syndicate led by Ahren Innovation Capital on the strength of its technology for converting one human cell type into another human cell type. In the case of the Sangamo deal, Mogrify will use the platform to convert induced pluripotent stem cells and embryonic stem cells into regulatory T cells.

RELATED:Bristol Myers' Juno unit enlists Oxford BioMedica for CAR-T work

The agreement with Sangamo tasks Mogrify with handling the discovery and optimization of the cell conversion technology. Sangamo will have exclusive rights to use the technology to generate Tregs. By applying its ZFP gene engineering technology to the Tregs, Sangamo plans to develop allogeneic cell therapies for use in the treatment of inflammatory and autoimmune diseases.

Sangamo is paying an upfront fee of undisclosed size to work with Mogrify. As programs based on the Tregs advance, Mogrify is in line to receive development and regulatory milestones, plus payments linked to product sales.

SPECIAL REPORT:Top biotech money raisers of 2019

News of the deal comes months after Sangamo got authorization in the U.K. to run a phase 1/2 trial of an autologous CAR-Treg cell therapy, TX200, in kidney transplant patients. Partnering with Mogrify will support Sangamos efforts to get allogeneic cell therapies into the clinic, building on its work with Kite Pharma to apply its technology to off-the-shelf cancer treatments such as CD19 CAR-T prospect KITE-037.

Having formed the pact with Sangamo, Mogrify now has two commercial deals with U.S. biopharma companies. The deals will provide Mogrify with a source of money as it works on internal cell therapy candidates in disease areas including musculoskeletal, autoimmune and cancer.

Visit link:

Sangamo taps Mogrify for off-the-shelf CAR-Treg project - FierceBiotech

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo), a genomic medicine company, have announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrifys proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamos zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.

Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy, said Dr. Darrin M. Disley OBE, CEO, Mogrify. The combination of Mogrifys proprietary systematic cell conversion technology and Sangamos regulatory T cell platform and proprietary ZFP platform is a natural fit. Sangamo is at the forefront of the development of a world-class engineered ZFP genome editing platform and we are very happy to be partnering with such an innovative company.

This license agreement provides Sangamo with access to Mogrifys cell conversion technology, which will diversify our options as we develop off-the-shelf allogeneic CAR-Treg cell therapies, said Jason Fontenot, SVP, Head of Cell Therapy at Sangamo. We expect this collaboration to accelerate our development of scalable and accessible CAR-Treg cell therapies, so that we can potentially deliver treatments to patients with inflammatory and autoimmune diseases more rapidly.

Mogrifys technology enables the transformation of any human cell type into any other human cell type. This transformation is achieved using transcription factors or small molecules identified using proprietary big data technologies. iPSCs and ESCs provide an evergreen starting material for the generation of Tregs, and facilitate more complex engineering and greater manufacturing scalability, potentially enabling the resulting therapies to be more cost-effective and thus more accessible to larger patient populations.

Under the terms of the agreement, Mogrify will be responsible for the discovery and optimization of the cell conversion technology from iPSCs or ESCs to regulatory T cells, and Sangamo will be granted exclusive rights to use Mogrifys technology to create Tregs from iPSCs or ESCs. Sangamo expects to then use its ZFP gene-engineering technology and therapeutic development capabilities to transform these Tregs into novel off-the-shelf allogeneic CAR-Treg cell therapy candidates and hopes to take them through clinical development through to registration for the treatment of inflammatory and autoimmune diseases.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Read the rest here:

Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify's iPSC- and ESC-derived regulatory T cells - SelectScience

Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the countrys compassionate use program.The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristems placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.In the US case, the patient was treated with the companys PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks.The companys president and CEO, Yaky Yanay, said that although Pluristem is focused on a planned multinational clinical trial for the treatment of complications associated with coronavirus, it does hope to expand treatment under compassionate use in other countries at the same time.

Specifically, the US treatment was administered under the US Food and Drug Administrations Single Patient Expanded Access Program, which is part of the US Coronavirus Treatment Acceleration Program - an emergency program aimed at getting treatments to corona patients as quickly as possible.

In Israel, the six patients were treated at three different Israeli medical centers for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.

Pluristems PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties, meaning they induce the immune systems natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).

Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.

We are pleased with this initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems, Yanay said.

View original post here:

Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post

Allosource

Global Stem Cell Therapy Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=002

Global Stem Cell Therapy Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Stem Cell Therapy sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Stem Cell Therapy sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Stem Cell Therapy sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Stem Cell Therapy market and formulate optimal business strategies to maximize market growth.

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Stem Cell Therapy market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Stem Cell Therapy market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Stem Cell Therapy Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

The rest is here:

Stem Cell Therapy Market Overview by 2026: Verified Market Research - Cole of Duty

We have another fuzzy snapshot of clinical trial data on Gileads remdesivir in coronavirus patients, and at first glance this one looks bleak for the most advanced therapy now in the clinic for Covid-19.

The Financial Times and STAT both reported on an abstract of the Chinese study, this one using a control group that appeared temporarily on the WHO site after it was posted accidentally. Its still not been peer reviewed, but Salim Syed at Mizuho summarized the numbers:Of the 237 patients that were studied in the trial, 158 were on remdesivir, and 79 were on control, and remdesivir did not produce a difference in mortality at 28 days (13.9% for remdesivir vs 12.8% for control).Taken at face value, thats a nasty failure. The stock dropped 4% this afternoon. BUT you cant take it at face value, as Gilead pointed out in a followup statement.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

The rest is here:

Sangamo ties up with a newcomer in the cell therapy field; LabCorp wins FDA authorization of latest Covid-19 test - Endpoints News

Given the debilitating impact of COVID-19 (Coronavirus) on the Animal Stem Cell Therapy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Animal Stem Cell Therapy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

The report provides both quantitative and qualitative information of global Animal Stem Cell Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Animal Stem Cell Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Animal Stem Cell Therapy market was valued at USD _ million/billion.

This research report based on Animal Stem Cell Therapy market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Animal Stem Cell Therapy market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Animal Stem Cell Therapy industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Animal Stem Cell Therapy Market Overview:

The Research projects that the Animal Stem Cell Therapy market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Animal Stem Cell Therapy Market:

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

The Questions Answered by Animal Stem Cell Therapy Market Report:

And Many More.

Read the original post:

World coronavirus Dispatch: Animal Stem Cell Therapy Expected to Witness a Fast-paced Growth Over the Forecast Period 2017 2025 - Latest Herald

Supposed therapies range from stem cell infusions to acupuncture and ozone treatments

April 24, 2020 - The Federal Trade Commission announced it has sent 21 additional letters warning marketers throughout the United States to stop making unsubstantiated claims that their products and therapies can treat or prevent coronavirus (COVID-19). This is third set of warning letters the FTC has sent to sellers of such products as part of its ongoing efforts to protect consumers from COVID-19 related scams.

The FTCpreviously sent warning lettersto the sellers of supplements including colloidal silver, teas, essential oils, and other products pitched as scientifically proven coronavirus treatments. The letters announced today, however, address a wider range of products and supposed treatments, including some that may appear more medically sophisticated to consumers, such as acupuncture, intravenous (IV) therapies with high doses of Vitamin C, ozone therapy, and purported stem cell treatments. However, there is currently no scientific evidence that these products or services can treat or cure coronavirus.

The FTC sent the letters announced today to the companies and individuals listed below. The recipients are grouped based on the type of therapy, product, or service they pitched to supposedly prevent or treat coronavirus disease.

General Therapy Products, Vitamins, and Supplements:

IV Therapy and Related Treatments:

Ozone Therapy:

Stem Cell Therapy:

In the letters, the FTC states that one or more of the efficacy claims made by the marketers are unsubstantiated because they are not supported by scientific evidence, and therefore violate the FTC Act. The letters advise the recipients to immediately cease making all claims that their products can treat or cure coronavirus and to notify the FTC within 48 hours about the specific actions they have taken to address the agencys concerns.

The letters note that if the false claims do not cease, the Commission may seek a federal court injunction and an order requiring money to be refunded to consumers.

The letters announced today are the latest round of warnings the FTC has sent to sellers of products pitched as able treat or prevent coronavirus. The Commission also has sentletters to several Voice over Internet Protocol (VoIP) service providers, warning them that it is illegal to aid or facilitate the transmission of pre-recorded telemarketing robocalls pitching supposed coronavirus-related products or services.

PRESS RELEASE REFERENCE:

See original here:

FTC Sends 21 Letters Warning Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Treat Coronavirus - Sierra...

NEW YORK, March 24, 2020 /PRNewswire/ --

INTRODUCTIONAccording to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness. The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.

Read the full report: https://www.reportlinker.com/p05877767/?utm_source=PRN

Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms. In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel (2018), MACI (2016), Stempeucel (2016) and Strimvelis (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors. Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.

SCOPE OF THE REPORTThe "Global Stem Cell Market: Focus on Clinical Therapies, 20202030 (based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. In addition, information on the various technology platforms being actively used for the development of stem cell therapies has been provided. Identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). Detailed profiles of the key industry players engaged in the development of stem cell-based therapies, featuring a brief overview of the company (such as year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available)), details of their respective product portfolio and an informed future outlook. An assessment of over 20 commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat the same conditions, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects. An analysis of potential growth opportunities for stem cell therapies across different therapeutic areas in the established / emerging regions, based on the Ansoff growth model. An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation. A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials. A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner. A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies. An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates. An analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies. The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end-users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: William L Rust (Founder and Chief Executive Officer, Seraxis) Xuejun Huang Parsons (Chief Executive Officer, Xcelthera) Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem) Kikuo Yasui (Director and Chief Operating Officer, Heartseed) Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock) Gilles Devillers (President, Bio Elpida) Fiona Bellot (Business Development Manager, Roslin Cell Therapies) David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of stem cell therapies market and their likely evolution in the short-mid term and long term.

Chapter 3 provides a brief introduction to stem cell therapies, highlighting details regarding their development and administration. It includes information on various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of therapy administration and the disease indications targeted by such interventions. It also emphasizes on the challenges related to the development of such therapy candidates. In addition, it provides a detailed description of the regulatory landscape related to stem cell therapies across various geographies, such as the North America (primarily the US), Europe and other key global regions. Further, it includes an analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research.

Chapter 4 includes information on over 280 stem cell-based therapies approved / under clinical development, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. It also focuses on the identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). In addition, information on the various technology platforms being actively used for the development of stem cell therapies, has been provided.

Chapter 5 features detailed profiles of key industry players engaged in the development of stem cell-based therapies (shortlisted on the basis of number of pipeline products). Each profile features a brief overview of the company along with the information on year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available), details on their respective product portfolio, and an informed future outlook.Chapter 6 presents an assessment of over 20 most commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat them, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects.

Chapter 7 highlights an analysis of potential growth opportunities for stem cell therapies across different therapeutic areas in the established / emerging markets, based on the Ansoff growth model.

Chapter 8 provides an analysis of more than 1,500 grants that were awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November) based on the important parameters associated with grants, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation.

Chapter 9 provides a detailed clinical trial analysis of more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 10 features a review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.

Chapter 11 presents a detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.

Chapter 12 features an elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell therapy market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy domain. We have inputs from William L Rust (Founder and Chief Executive Officer, Seraxis), Xuejun Huang Parsons (Chief Executive Officer, Xcelthera), Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem), Kikuo Yasui (Director and Chief Operating Officer, Heartseed), Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock), Gilles Devillers (President, Bio Elpida), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Read the full report: https://www.reportlinker.com/p05877767/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-stem-cell-market-focus-on-clinical-therapies-20202030-based-on-source--origin--type--lineage--and-potency--301028853.html

SOURCE Reportlinker

Read this article:

Global Stem Cell Market: Focus on Clinical Therapies, 2020-2030 (based on Source ; Origin ; Type ; Lineage ; and Potency ) - P&T Community

The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200323005764/en/

Technavio has published a latest market research report titled Global Autologous Cell Therapy Market 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Story continues

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005764/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read more here:

Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Yahoo...

Ever since the novel coronavirus, or COVID-19, was first reported in China's Wuhan city, the virus has spread to more than 196 countries and territories around the world with393,284 confirmed cases and17,161 deaths so far. In India, the maximum number of cases has been reported in the state of Maharashtra.The number of coronavirus cases in the country has risen to 519, with 10 deaths.

It is the need of the hour to find a solution for coronavirus.

Clinical trials in China are already testing the efficacy of stem cell therapies for COVID-19. Arecent clinical trialwith seven COVID-19 patients showed that a stem cell product improved patient outcome. According to research published in the peer-reviewed journalAging and Disease,mesenchymal stem cell (MSC) therapy could be effective in treating COVID-19.

Coronaviruses (CoV) belong to a large family of viruses leading to respiratory illnesses, such as common coldto more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute RespiratorySyndrome (SARS-CoV).

Earlier this year, a new strain of coronavirus was discovered, which was not previously identified in humanbeings, also known as the novel coronavirus (nCov). The symptoms of the infection are respiratory issues, fever, cough, shortness of breath, and breathingdifficulties. More severe cases of COVID-19 can cause pneumonia, severe acute respiratory syndrome, and kidneyfailure.

In recent years, scientific research hasshown that MSCs have properties that maymake them very useful to repair damaged tissues in the patients respiratory system and promotefaster healing and recovery.Umbilical cord tissueis particularly rich inthese cells, which is why many parents arechoosing to store them at birth.

MSCs can reduce the overproduction of immune cells caused by a reaction to the virus and reduce excessive levels of inflammatory substances, thus regulating the immune system.

Currently, many vaccines or drugs are being tested to deal with coronavirus. There is widespread fear and phobia among the population. Why not use your own defence system rather than searching for drugs to tackle the virus?

MSCs are multi-potent cells that have been widely used for tissue regeneration and immunomodulation, and can be a potential solution. The infusion of autologous and allogenic MSCs has been proven safe and effective in tissue repair and disease modulation. MSCs have anti-inflammatory, antimicrobial properties; therefore, they have the potential to control inflammatory conditions, possibly viral diseases, and may reduce mortality.

Another interesting therapeutic avenue is immunotherapy. Natural killer (NK) cells, a component of our innate immune system, play an important role in tackling malignancies as well as virally infected cells. These cells serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection. Thus, NK cell therapy can be safe and effective in the management of COVID-19.

We need to ensure control of person-to-person transmission of the infection. Therefore, stringent isolation/quarantine measures are important until complete recovery of an infected individual.

(Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of YourStory.)

How has the coronavirus outbreak disrupted your life? and how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to editorial@yourstory.com

See the article here:

Can cell-based therapy be helpful in tackling coronavirus? - YourStory

The first patients have now been recruited for a new UK clinical trial of potential drug treatments for Covid-19.

There are currently no specific treatments for the virus but researchers from the University of Oxford will explore whether any existing medications are effective.

There is an urgent need for reliable evidence on the best care for patients with Covid-19"

Peter Horby

In the first instance, the Randomised Evaluation of Covid-19 Therapy (RECOVERY) trial will look at lopinavir-ritonavir, normally used to treat HIV, and the steroid dexamethasone, which is used in a wide range of conditions to reduce inflammation.

The drugs were recommended for inclusion by an expert panel that advises the chief medical officer in England and in the future it is anticipated that the trial will be expanded to assess the impact of other potential treatments.

The chance to join the trial will be offered to adult inpatients who have tested positive for Covid-19 in NHS hospitals and who have not been excluded for medical reasons.

All participants will receive the usual standard of care and will also be chosen at random to receive one of the two drugs being studied or no additional medication.

This will enable researchers to see whether any of the possible new treatments are more or less effective than those currently used for patients with the new strain of coronavirus.

In this way we can rapidly assess the value of potential treatments for Covid-19"

Martin Landray

Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine, University of Oxford, is chief Investigator for the trial.

He said: There is an urgent need for reliable evidence on the best care for patients with Covid-19.

Providing possible new treatments through a well-designed clinical trial is the best way to get that evidence.

Deputy chief investigator Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health, University of Oxford, added: The streamlined design of this clinical trial allows consenting patients to be enrolled in large numbers easily and without compromising patient safety or adding significantly to the workload of busy hospitals and their staff.

In this way we can rapidly assess the value of potential treatments for Covid-19 and provide reliable information on the best ways to treat patients with this disease.

English chief medical officer Chris Whitty and NHS England medical director Stephen Powis have written to NHS trusts in England asking them to fully support the new trial.

Original post:

Clinical trial to find effective Covid-19 treatments gets underway - Nursing Times

Washington University School of Medicinein St. Louis released a newstudyabout the effectiveness of immunotherapy based on the age of the cells used. The study, published in the journalDevelopmental Cell,showed that these natural killer cells seem to be more effective when they are young. Natural killer (NK) cells, as they're called, are used in immunotherapy to treat cancer using the body's immune cells or immune cells from a matched donor.

"We are trying to improve the effectiveness of immunotherapy for more patients," said senior author Christopher M. Sturgeon, Ph.D., an assistant professor of medicine.

Typically, NK cells used in investigational immunotherapy are adult and come from the patient or donor bone marrow. While these therapies can work, they don't work for everyone.

In contrast, young NK cells do not use the patient's cell or donor cells. These early NK cells, typically formed in the yolk sac in the early embryo, are instead able to be created with human pluripotent stem cells. They can be manufactured quickly by most academic medical centers, thus eliminating the time it takes to process patient's or donor's cells for typical NK cell therapy.

"This special source of natural killer cells has the potential to fill some of the gaps remaining with adult NK cell therapy. There is early evidence that they are more consistent in their effectiveness, and we would not need to process cells from a donor or the patient. They could be manufactured from existing cell supplies following the strict federal guidelines for good manufacturing practices. The characteristics of these cells let us envision a supply of them ready to pull off the shelf whenever a patient needs them," Sturgeon said.

Instudieswith mice using the lab-developed human pluripotent stem cells to create early NK cells, researchers found positive results. These cells were significantly better at degranulation than adult NK cells. Even cells from umbilical cord blood did not respond as well as the early NK cells. Additionally, early NK cells are a particular type of short-lived immune cell, meaning that even if the cells cause harm, they aren't in the body for very long. However, NK cells, in general, do not attack the body's healthy tissues significantly, unlike many T cell therapies.

"Based on their unique behavior alone, there is one small clinical trial of these cells that is ongoing. Now that we know how to manufacture them and how they work, it opens the door for more trials and for improving upon their function, " Sturgeon said.

More research will need to be put into understanding why these special cells only show up in the early embryo and where they go after.

The origin and why they work so well is still a complete mystery.

"We can only speculate at this point, but it's possible that during early embryonic development, when there is so much rapid cell division, these cells are there as a surveillance mechanism to protect against pediatric cancers or infection," he said.

In addition to the early NK cells, pluripotent stem cells also have the potential to bring about many other different cell types, creating more possibilities.

Read more from the original source:

Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace

The global Canine Stem Cell Therapy market registered a value of ~US$ xx Mn/Bn in 2019 and is spectated to grow at CAGR of xx% during the foreseeable period 2019-2029. In terms of product type, segment holds the largest share, while segment 1 and segment 2 hold significant share in terms of end use.

The Canine Stem Cell Therapy market study outlines the key regions Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2), region 3 (Country 1, Country 2) and region 4 (Country 1, Country 2). All the consumption trends and adoption patterns of the Canine Stem Cell Therapy are covered in the report. Prominent players, including player 1, player 2, player 3 and player 4, among others, account for substantial shares in the global Canine Stem Cell Therapy market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

The Canine Stem Cell Therapy market research answers important questions, including the following:

The Canine Stem Cell Therapy market research serves a platter of the following information:

Why go for Canine Stem Cell Therapy Market Research?

Our analysts work irrespective of the time-zone, the result, we are being recognized worldwide. We abide by the notion that each client has his/her own set of requirements. With extensive primary and secondary research, our experts churn out the most accurate information regarding the desired the Canine Stem Cell Therapy market.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Read more:

Canine Stem Cell Therapy Market top key players, size, Analysis, growth, research, Types, Regions and Forecast from 2019-2024 - Packaging News 24